Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential
Metformin is the first-line oral medication for treating type 2 diabetes mellitus (T2DM). In the current study, an untargeted lipidomic analytical approach was used to investigate the alterations in the serum lipidome of a cohort of 89 participants, including healthy lean controls and obese diabetic...
Saved in:
Main Authors: | Muhammad Mujammami (Author), Shereen M. Aleidi (Author), Adriana Zardini Buzatto (Author), Awad Alshahrani (Author), Reem H. AlMalki (Author), Hicham Benabdelkamel (Author), Mohammed Al Dubayee (Author), Liang Li (Author), Ahmad Aljada (Author), Anas M. Abdel Rahman (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Obesity Connected Metabolic Changes in Type 2 Diabetic Patients Treated With Metformin
by: Shereen M. Aleidi, et al.
Published: (2021) -
Proteomic Profiling Identifies Distinct Regulation of Proteins in Obese Diabetic Patients Treated with Metformin
by: Awad Alshahrani, et al.
Published: (2023) -
A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach
by: Lina A. Dahabiyeh, et al.
Published: (2021) -
Untargeted metabolomics reveals the impact of Liraglutide treatment on metabolome profiling and metabolic pathways in type-2 diabetes mellitus
by: Hicham Benabdelkamel, et al.
Published: (2024) -
Novel metabolic and lipidomic biomarkers of sarcopenia
by: Wei‐Hsiang Hsu, et al.
Published: (2024)